SCHEDULE: Janus Henderson Cuts Avidity Biosciences Stake Below 5%

Janus Henderson Group plc has reported a reduction in its beneficial ownership of Avidity Biosciences, Inc. common stock to 4.6% as of December 31, 2025.

Summary

• Janus Henderson Group plc, through its Asset Managers, beneficially owns 6,939,503 shares of Avidity Biosciences, Inc. common stock.
• This represents 4.6% of the class of securities, which is below the 5% threshold for significant institutional ownership.
• The filing is an Amendment No. 4 to a Schedule 13G, indicating a change from previous ownership disclosures.
• The shares are held in Managed Portfolios, where Asset Managers exercise shared voting and dispositive power.
• The acquisition and holding of these securities are in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative signal, as a major institutional investor has reduced its stake below a key reporting threshold, potentially indicating diminished confidence or a strategic divestment.

Positives

• Janus Henderson Group plc, a significant institutional investor, continues to hold a substantial stake of 6,939,503 shares in Avidity Biosciences, Inc.
• The holding is for investment purposes in the ordinary course of business, not for control, which aligns with passive institutional investment strategies.

Negatives

• Janus Henderson Group plc's beneficial ownership has decreased to 4.6%, falling below the 5% threshold for significant institutional ownership. This reduction, reported in Amendment No. 4, suggests a potential decrease in the firm's investment or conviction in the company.

Risks

• The reduction of a significant institutional stake could signal a lack of confidence or a re-evaluation of Avidity Biosciences' future prospects by a major investor.
• Asset Managers disclaim any right to receive dividends or proceeds from the sale of securities held in Managed Portfolios, which means their beneficial ownership is primarily for voting and dispositive power, not direct economic interest.

Future Outlook

Not applicable as this filing is an ownership disclosure and does not contain forward-looking statements or guidance from the issuer.

Management Comments

• To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

StockSavvy.ai notes that institutional ownership changes, particularly reductions below key thresholds like 5%, are closely watched by the market as they can indicate shifts in investor sentiment or strategy regarding a company within the biotechnology sector. While Janus Henderson remains an investor, the decrease below 5% suggests a re-evaluation compared to peers who might be increasing stakes or maintaining higher levels of ownership.

Management Changes

Stakeholder Impact

• Shareholders: May interpret the reduction in institutional ownership as a negative signal, potentially impacting investor confidence and stock valuation.

Key Dates

Recommendation

The reduction of Janus Henderson Group plc's stake in Avidity Biosciences to below the 5% threshold, as indicated by this Amendment No. 4 filing, suggests a potential loss of conviction or a strategic divestment by a major institutional investor. This could signal underlying concerns or a re-evaluation of the company's prospects, warranting a 'sell' recommendation for investors.

Keywords

Avidity Biosciences, Janus Henderson, Institutional Ownership, Schedule 13G, Common Stock, Biotechnology, Investment Management, Shareholding